SCHEMBL13307487

SCHEMBL13307487

CCOC(=O)c1cc(CBr)cc(C(=O)CC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA14 Q9ULX7 3/20 0.50
CYP4F2 P78329 2/20 0.47
CYP4A11 Q02928 2/20 0.47
CYP2C19 P33261 2/20 0.44
CYP2C9 P11712 1/20 0.44
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
HSD17B2 P37059 1/20 0.42
CYP1A2 P05177 2/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAOA P21397 1/20 0.41
MEP1B Q16820 1/20 0.40
CYP2D6 P10635 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2212198 0.92 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL7592102 0.88 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL4652540 0.85 CYP2C19 (0.57) CA12CA1CA2CA7CA9
SCHEMBL13307492 0.85 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL9885271 0.85 CA12 (0.55) CA12CA1CA2CA7CA9
SCHEMBL16528056 0.83 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL13307516 0.83 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL13307484 0.83 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL13307493 0.81 CYP2C19 (0.60) CA12CA1CA2CA7CA9
SCHEMBL3348484 0.81 CA12 (0.44) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CA12 4160/4885CA1 582/4885CA2 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.